Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is Amgen's Acquisition of Five Prime a Good Move for the Big Biotech?

TheMotleyFool

0 0

Is Amgen's Acquisition of Five Prime a Good Move for the Big Biotech?

Amgen (NASDAQ: AMGN) recently announced plans to acquire Five Prime Therapeutics (NASDAQ: FPRX) for approximately $1.9 billion. The deal gives Amgen rights to bemarituzumab, which has made it through phase 2 testing. In this video from Motley Fool Live, recorded on March 8, Fool.com contributors Brian Orelli and Keith Speights discuss why Amgen needs to seek out this potential growth and whether Five Prime's pipeline is worth the premium Amgen paid for it.